Toni K. Choueiri, MD reflects on recent RCC advances.
Sexual Disorders of Patients With Metastatic Renal Cell Carcinoma (mRCC) Treated With Antiangiogenic Therapies
Targeted therapies, in particular antiangiogenic therapies (AATs), have become the standard of treatment for metastatic renal cell carcinoma (mRCC). Although common adverse effects like fatigue have been well-established, sexual disorders induced by these treatments, although often reported, have been poorly evaluated.
Combined assessment of low PGRMC1/positive ATP1A1 levels has enhanced prognostic value for renal cell carcinoma
Progesterone receptor membrane component 1 (PGRMC1) and Na+/K+‑ATPase α1 subunit (ATP1A1) are two proteins associated with the clinical prognosis of renal cell carcinoma (RCC) and RCC cell proliferation. However, the two proteins have been previously studied independently, and their combined influence on the clinical outcome of RCC remains unclear.
Walter Stadler, M.D., who is on our medical steering committee, is one of the panelists in this video.
A comprehensive study by the Keck School of Medicine of USC, which has found that robotic partial nephrectomy offers significantly better patient outcomes.
Comprehensive analysis of a novel lncRNA profile reveals potential prognostic biomarkers in clear cell renal cell carcinoma
Clear cell renal cell carcinoma (ccRCC) is the main subtype of malignant kidney cancer. Long non‑coding RNA (lncRNA) serves a key role in predicting survival in patients with cancer.
Efficacy of Nivolumab in a Patient with Metastatic Renal Cell Carcinoma and End-Stage Renal Disease on Dialysis
Treatment of patients with metastatic renal cell carcinoma (mRCC) and end-stage renal disease (ESRD) on dialysis poses a therapeutic challenge, particularly as this patient group was excluded from the pivotal clinical trials. In addition, there is uncertainty regarding drug dosing/pharmacokinetics, lack of safety and efficacy data, and potential for increased toxicity when using targeted therapy or immunotherapy for the management of patients with mRCC on dialysis.
Patients with incidental pathologic T3a (pT3a) upstaging after partial nephrectomy (PN) have significantly reduced recurrence-free survival (RFS) and cancer-specific survival (CSS) when compared to patients whose disease isn't upstages from pT1a-b.
The short-term oncological and functional outcomes for partial nephrectomy are comparable for laparoscopic partial nephrectomy following selective embolization of tumor (LPNE) in a hybrid operating room and robot-assisted partial nephrectomy (RAPN). A longer follow-up and a larger cohort of patients would be necessary to verify the benefits of LPNE, which appears to be a very interesting alternative to RAPN.
Over a 25-year period, the proportion of patients with high-risk clinical T1 tumors increased by nearly 20 percent and clinical tumor size decreased from 8.4 to 6.2 cm, an Italian study found.